928655-63-4
928655-63-4 structure
- Name: HPN-01
- Chemical Name: HPN-01
- CAS Number: 928655-63-4
- Molecular Formula: C19H16ClN3O3S
- Molecular Weight: 401.87
- Catalog: Signaling Pathways NF-κB IKK
- Create Date: 2020-01-23 20:20:51
- Modify Date: 2025-08-25 11:53:21
-
HPN-01 is a potent and selective IKK inhibitor, with pIC50 values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2[1].
| Name | HPN-01 |
|---|
| Description | HPN-01 is a potent and selective IKK inhibitor, with pIC50 values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2[1]. |
|---|---|
| Related Catalog | |
| Target |
IKK-α:6.4 (pIC50) IKK-β:7.0 (pIC50) IKK-ε:<4.8 (pIC50) |
| In Vitro | HPN-01 effectively suppress LPS-stimulated secretion of TNF-α, IL-1β, and IL-6 from human PBMCs (pIC50=6.1, 6.4, and 5.7, respectively). HPN-01 also inhibits TNF-α-induced NF-κB nuclear translocation in human lung fibroblast cells (pIC50=5.7)[1]. HPN-01 inhibits the expression of SREBP-1and SREBP-2 in cultured primary human hepatocytes with IC50s of 1.71 μΜ and 3.43 μΜ, respectively. HPN-01 is being development for the treatment of nonalcoholic fatty liver disease (NAFLD)[2]. |
| References |
[2]. Ke Li, et al. Amino-aryl-benzamide compounds and methods of use thereof.WO2018204775A1. |
| Molecular Formula | C19H16ClN3O3S |
|---|---|
| Molecular Weight | 401.87 |